{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-10514"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-10514","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Alpha Synuclein: A therapeutic target and biomarker for Parkinson’s Disease","abstract":"Parkinson’s Disease is the second most common neurodegenerative disease after Alzheimer’s Disease, and the most common motor disorder. In fact, nearly a third of those with AD have PD. A major hallmark of PD is the appearance of Lewy Bodies, proteinaceous cytoplasm inclusions, that build up and spread throughout the CNS in a prion like fashion. The major component of these Lewy Bodies is a protein called alpha-synuclein. Alpha-syn is a 14kDa protein made of 140 amino acids and found in the presynaptic ends of CNS neurons, acting as a chaperone and regulator. The protein is also found in the rest of the body besides the liver, most importantly in the blood. It has been shown in various studies that targeting alpha-syn can slow down or mitigate the effects of PD. It has also been shown that alpha-syn levels in the blood significantly increase in PD patients compared to non-PD patients. This makes alpha-syn a good biomarker for both diagnosis and potential treatment. However, being able to quickly identify alpha-syn is paramount for quick and efficient diagnosis. In this experiment, I use antibodies, 1H5 and 2A4, to quickly identify relative amounts of alpha-syn in human PD blood plasma. I also used the DOT Blot apparatus as a quick throughput method of antibody staining. The results showed that these monoclonal antibodies combined with using a DOT Blot technique could be used for clinical diagnosis or treatment with proper treatment.","abstract_html":"Parkinson’s Disease is the second most common neurodegenerative disease after Alzheimer’s Disease, and the most common motor disorder. In fact, nearly a third of those with AD have PD. A major hallmark of PD is the appearance of Lewy Bodies, proteinaceous cytoplasm inclusions, that build up and spread throughout the CNS in a prion like fashion. The major component of these Lewy Bodies is a protein called alpha-synuclein. Alpha-syn is a 14kDa protein made of 140 amino acids and found in the presynaptic ends of CNS neurons, acting as a chaperone and regulator. The protein is also found in the rest of the body besides the liver, most importantly in the blood. It has been shown in various studies that targeting alpha-syn can slow down or mitigate the effects of PD. It has also been shown that alpha-syn levels in the blood significantly increase in PD patients compared to non-PD patients. This makes alpha-syn a good biomarker for both diagnosis and potential treatment. However, being able to quickly identify alpha-syn is paramount for quick and efficient diagnosis. In this experiment, I use antibodies, 1H5 and 2A4, to quickly identify relative amounts of alpha-syn in human PD blood plasma. I also used the DOT Blot apparatus as a quick throughput method of antibody staining. The results showed that these monoclonal antibodies combined with using a DOT Blot technique could be used for clinical diagnosis or treatment with proper treatment.","abstract_has_math":false,"creators":["Chase, Max"],"institution":"University of South Florida","degree_name":"Master of Science (M.S.)","degree_level":"Thesis","degree_discipline":"Public Health","degree_department":null,"school":null,"contributors":["Chaunhai Cao, Ph.D.","Umesh Jinwal, Ph.D.","Wanling Xuan, Ph.D.","Qingyu Zhou, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-04-21T07:00:00Z","date_published":"2022-04-21T07:00:00Z","updated_at":"2026-11-19T08:47:28Z","subjects":["tauopathies","diagnosis","aging","prion-like","Nanoscience and Nanotechnology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/9317","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/9317","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-10514","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Chaunhai Cao, Ph.D.","Umesh Jinwal, Ph.D.","Wanling Xuan, Ph.D.","Qingyu Zhou, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Chase, Max"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-04-21T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Public Health"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis","M.S."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (M.S.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["tauopathies","diagnosis","aging","prion-like","Nanoscience and Nanotechnology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/9317"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Parkinson’s Disease is the second most common neurodegenerative disease after Alzheimer’s Disease, and the most common motor disorder. In fact, nearly a third of those with AD have PD. A major hallmark of PD is the appearance of Lewy Bodies, proteinaceous cytoplasm inclusions, that build up and spread throughout the CNS in a prion like fashion. The major component of these Lewy Bodies is a protein called alpha-synuclein. Alpha-syn is a 14kDa protein made of 140 amino acids and found in the presynaptic ends of CNS neurons, acting as a chaperone and regulator. The protein is also found in the rest of the body besides the liver, most importantly in the blood. It has been shown in various studies that targeting alpha-syn can slow down or mitigate the effects of PD. It has also been shown that alpha-syn levels in the blood significantly increase in PD patients compared to non-PD patients. This makes alpha-syn a good biomarker for both diagnosis and potential treatment. However, being able to quickly identify alpha-syn is paramount for quick and efficient diagnosis. In this experiment, I use antibodies, 1H5 and 2A4, to quickly identify relative amounts of alpha-syn in human PD blood plasma. I also used the DOT Blot apparatus as a quick throughput method of antibody staining. The results showed that these monoclonal antibodies combined with using a DOT Blot technique could be used for clinical diagnosis or treatment with proper treatment."]},{"key":"dc:title","label":"Title","values":["Alpha Synuclein: A therapeutic target and biomarker for Parkinson’s Disease"]}]}],"canonical_facts":{"dc:contributor":["Chaunhai Cao, Ph.D.","Umesh Jinwal, Ph.D.","Wanling Xuan, Ph.D.","Qingyu Zhou, Ph.D."],"dc:creator":["Chase, Max"],"dc:date":["2022-04-21T07:00:00Z"],"dc:description":["Parkinson’s Disease is the second most common neurodegenerative disease after Alzheimer’s Disease, and the most common motor disorder. In fact, nearly a third of those with AD have PD. A major hallmark of PD is the appearance of Lewy Bodies, proteinaceous cytoplasm inclusions, that build up and spread throughout the CNS in a prion like fashion. The major component of these Lewy Bodies is a protein called alpha-synuclein. Alpha-syn is a 14kDa protein made of 140 amino acids and found in the presynaptic ends of CNS neurons, acting as a chaperone and regulator. The protein is also found in the rest of the body besides the liver, most importantly in the blood. It has been shown in various studies that targeting alpha-syn can slow down or mitigate the effects of PD. It has also been shown that alpha-syn levels in the blood significantly increase in PD patients compared to non-PD patients. This makes alpha-syn a good biomarker for both diagnosis and potential treatment. However, being able to quickly identify alpha-syn is paramount for quick and efficient diagnosis. In this experiment, I use antibodies, 1H5 and 2A4, to quickly identify relative amounts of alpha-syn in human PD blood plasma. I also used the DOT Blot apparatus as a quick throughput method of antibody staining. The results showed that these monoclonal antibodies combined with using a DOT Blot technique could be used for clinical diagnosis or treatment with proper treatment."],"dc:identifier":["https://digitalcommons.usf.edu/etd/9317"],"dc:subject":["tauopathies","diagnosis","aging","prion-like","Nanoscience and Nanotechnology"],"dc:title":["Alpha Synuclein: A therapeutic target and biomarker for Parkinson’s Disease"],"thesis:degree_discipline":["Public Health"],"thesis:degree_level":["Thesis","M.S."],"thesis:degree_name":["Master of Science (M.S.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:47:28Z"}